ICG (LSE:ICG) is set to present at the Sachs Associates 26th Annual Biotech in Europe Forum on 7 October 2026, spotlighting its life sciences activity for investors tracking the group's sector exposure.
ICG's share price has softened over 2026, with the stock down 12.5% year to date and 5.5% over the past month. However, the 3 year total shareholder return of 48.51% still points to stronger longer run outcomes than the recent pullback suggests.
Look beyond ICG and track other alternative asset managers with meaningful healthcare exposure by reviewing the hand picked 7 healthcare AI stocks that could benefit from similar life sciences tailwinds.
ICG has built a broad, cash generating alternatives platform, yet the share price is still 12.5% lower for 2026. Is that a sensible valuation reset, or an overly cautious one?
Most Popular Narrative: 28% Undervalued
ICG's most followed valuation story pegs fair value around £25.11 per share, well above the last close of £17.99. This puts the current pullback in a very different light.
ICG's fee related earnings reached £350m in FY26 with a 47% FRE margin and higher fee rate strategies now providing more than 75% of management fees, which supports the view that further mix shift into these areas could lift margins and earnings power.
See why 14 investors see ICG as 28% undervalued .
Result: Fair Value of £25.11 (UNDERVALUED)
Still, this undervaluation story for ICG can unravel if private equity exits stay muted or if intense deal competition starts to squeeze fee margins.
Find out about the key risks to this ICG narrative .
Next Steps
Mixed signals around ICG can be confusing, so move quickly, review the underlying metrics for yourself, and weigh both the upside and the red flags by checking the 5 key rewards and 1 important warning sign .
Looking for more investment ideas beyond ICG?
If ICG has sharpened your focus on where capital can work harder, do not stop here. A broader watchlist could be the difference between spotting opportunity early and watching it pass by.
-
Target future growth stories by reviewing the 5 high quality undiscovered gems that pair solid fundamentals with under the radar potential.
-
Build a steadier core by assessing the 4 resilient stocks with low risk scores designed to prioritise resilience when conditions turn choppy.
-
Strengthen your income stream by analysing the 1 dividend fortresses that focus on higher yielding businesses with robust profiles.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include ICG.L .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
